View in EDS

Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategies.

Saved in:
Bibliographic Details
Title: Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategies.
Authors: Yu Y; Biostatistics Shared Resources, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA., Murphy MK; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA., Tan V; Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA., Knight RJ; Cellular Therapy Laboratory, Hospital and Clinics, Oregon Health and Science University, Portland, Oregon, USA., Estalilla K; Cellular Therapy Laboratory, Hospital and Clinics, Oregon Health and Science University, Portland, Oregon, USA., Slater SE; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA., Kaempf A; Biostatistics Shared Resources, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA., Gandhi A; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA., Meyers G; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA., Cook RJ; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA., Maziarz RT; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA., Newell LF; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA. Electronic address: newelll@ohsu.edu.
Source: Cytotherapy [Cytotherapy] 2026 Apr; Vol. 28 (4), pp. 102005. Date of Electronic Publication: 2025 Nov 17.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 100895309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-2566 (Electronic) Linking ISSN: 14653249 NLM ISO Abbreviation: Cytotherapy Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41719957
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yu+Y%22">Yu Y</searchLink>; Biostatistics Shared Resources, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Murphy+MK%22">Murphy MK</searchLink>; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Tan+V%22">Tan V</searchLink>; Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Knight+RJ%22">Knight RJ</searchLink>; Cellular Therapy Laboratory, Hospital and Clinics, Oregon Health and Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Estalilla+K%22">Estalilla K</searchLink>; Cellular Therapy Laboratory, Hospital and Clinics, Oregon Health and Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Slater+SE%22">Slater SE</searchLink>; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Kaempf+A%22">Kaempf A</searchLink>; Biostatistics Shared Resources, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Gandhi+A%22">Gandhi A</searchLink>; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Meyers+G%22">Meyers G</searchLink>; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Cook+RJ%22">Cook RJ</searchLink>; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Maziarz+RT%22">Maziarz RT</searchLink>; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.<br /><searchLink fieldCode="AU" term="%22Newell+LF%22">Newell LF</searchLink>; Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA. Electronic address: newelll@ohsu.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100895309%22">Cytotherapy</searchLink> [Cytotherapy] 2026 Apr; Vol. 28 (4), pp. 102005. <i>Date of Electronic Publication: </i>2025 Nov 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100895309 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1477-2566 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214653249%22">14653249 </searchLink><i>NLM ISO Abbreviation: </i>Cytotherapy <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41719957
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jcyt.2025.102005
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 102005
    Titles:
      – TitleFull: Impact of ABO compatibility on outcomes after allogeneic hematopoietic cell transplantation (HCT): increased risk of acute GVHD with ABO bidirectional mismatch, independent of traditional and emerging GVHD prophylaxis strategies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yu Y
      – PersonEntity:
          Name:
            NameFull: Murphy MK
      – PersonEntity:
          Name:
            NameFull: Tan V
      – PersonEntity:
          Name:
            NameFull: Knight RJ
      – PersonEntity:
          Name:
            NameFull: Estalilla K
      – PersonEntity:
          Name:
            NameFull: Slater SE
      – PersonEntity:
          Name:
            NameFull: Kaempf A
      – PersonEntity:
          Name:
            NameFull: Gandhi A
      – PersonEntity:
          Name:
            NameFull: Meyers G
      – PersonEntity:
          Name:
            NameFull: Cook RJ
      – PersonEntity:
          Name:
            NameFull: Maziarz RT
      – PersonEntity:
          Name:
            NameFull: Newell LF
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2026 Apr
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1477-2566
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Cytotherapy
              Type: main
ResultId 1